Zacks Research Weighs in on GSK plc’s Q4 2024 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Research analysts at Zacks Research upped their Q4 2024 EPS estimates for shares of GSK in a report released on Tuesday, June 25th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings per share of $0.84 for the quarter, up from their previous estimate of $0.83. The consensus estimate for GSK’s current full-year earnings is $4.11 per share. Zacks Research also issued estimates for GSK’s Q2 2025 earnings at $1.00 EPS.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.15. The company had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%.

Several other research firms have also weighed in on GSK. Citigroup raised shares of GSK to a “strong-buy” rating in a research note on Monday, June 24th. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. The Goldman Sachs Group began coverage on shares of GSK in a report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. Finally, Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

GSK Stock Down 0.4 %

GSK stock opened at $38.50 on Friday. The company’s 50 day simple moving average is $42.51 and its 200 day simple moving average is $41.17. GSK has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The firm has a market capitalization of $79.79 billion, a price-to-earnings ratio of 13.95, a PEG ratio of 1.17 and a beta of 0.66. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be issued a $0.3762 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This is an increase from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.91%. GSK’s dividend payout ratio (DPR) is 53.26%.

Institutional Trading of GSK

Hedge funds and other institutional investors have recently made changes to their positions in the business. Versant Capital Management Inc increased its holdings in GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after buying an additional 676 shares during the last quarter. Register Financial Advisors LLC acquired a new position in GSK during the first quarter worth $31,000. BKM Wealth Management LLC acquired a new position in GSK during the fourth quarter worth $32,000. Richardson Financial Services Inc. acquired a new position in GSK during the fourth quarter worth $40,000. Finally, Jones Financial Companies Lllp increased its holdings in GSK by 62.2% during the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after buying an additional 509 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.